Key clinical point: Adding trabectedin to PLD as third-line therapy significantly prolongs OS and PFS in BRCA1/2-mutated patients with advanced epithelial ovarian cancer.
Major finding: OS in BRCA1/2 patients: 34.2 vs. 20.9 months with trabectedin + PLD vs. PLD alone.
Study details: A randomized, open-label, phase 3 study of 576 patients.
Disclosures: The ET743-OVC-3006 trial was sponsored by Janssen Research & Development. Dr. Monk reported financial relationships (consulting, honoraria/reimbursement, and/or speaker’s bureau participation) with Janssen/Johnson & Johnson and more than 20 other pharmaceutical companies.
Monk B et al. SGO 2019: Abstract 20.